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Abstract: Endocrine tumors are neoplasms originating from specialized hormone-secreting cells.
They can develop as sporadic tumors, caused by somatic mutations, or in the context of familial
Mendelian inherited diseases. Congenital forms, manifesting as syndromic or non-syndromic
diseases, are caused by germinal heterozygote autosomal dominant mutations in oncogenes or tumor
suppressor genes. The genetic defect leads to a loss of cell growth control in target endocrine tissues
and to tumor development. In addition to the classical cancer manifestations, some affected patients
can manifest alterations of bone and mineral metabolism, presenting both as pathognomonic and/or
non-specific skeletal clinical features, which can be either secondary complications of endocrine
functioning primary tumors and/or a direct consequence of the gene mutation. Here, we specifically
review the current knowledge on possible direct roles of the genes that cause inherited endocrine
tumors in the regulation of bone modeling and remodeling by exploring functional in vitro and
in vivo studies highlighting how some of these genes participate in the regulation of molecular
pathways involved in bone and mineral metabolism homeostasis, and by describing the potential
direct effects of gene mutations on the development of skeletal and mineral metabolism clinical
features in patients.
Keywords: inherited endocrine tumors; oncogenes; tumor suppressor genes; bone tissue; bone
modeling; bone remodeling; skeletal clinical features
1. Introduction
The specific clinical affections of bone tissue, and/or the deregulation of bone and
mineral metabolism, leading to premature bone mass loss and osteoporosis, develop in a
percentage of patients affected by inherited endocrine tumors, as primary manifestations
of the syndrome and/or as a consequence of hormone-secreting neoplasms, being a cause
of morbidity and disability.
To date, the medical literature has poorly and marginally documented skeletal affec-
tions in inherited endocrine tumors, and a comprehensive and detailed review, focused on
the roles of the genetic determinants of these diseases in the regulation of bone and mineral
metabolism, and, possibly, in the development of skeletal manifestations, is missing.
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This review wants to offer clinicians an overview of the molecular mechanisms under-
lying bone and mineral metabolism alterations in different syndromic and non-syndromic
inherited endocrine tumors, as possible bases for targeted clinical managements of skeletal
pathological manifestations in these congenital diseases.
In this light, we specifically reviewed the current knowledge, derived from in vitro and
in vivo studies, about the possible role that some of the genes, whose germline mutations
are responsible for inherited endocrine tumors, may have in the regulation of molecular
pathways involved in skeletal development and bone and mineral metabolism homeostasis.
2. Inherited Endocrine Tumors
The term “endocrine tumors” indicates a heterogeneous group of neoplasms originat-
ing from specialized hormone-secreting cells and affecting the endocrine glands. Tumoral
cells maintain their hormone-secreting ability (functioning tumors; FTs) in a majority of
cases, or, in a small portion of endocrine tumors, they lose the capability of producing
hormones (non-functioning tumors; NFTs).
Endocrine tumors can develop as sporadic cancers caused by somatic mutations or
in the context of familial Mendelian inherited diseases. Congenital forms are caused by
germinal heterozygote autosomal dominant mutations in oncogenes or tumor suppressor
genes inherited from the affected parent, or, in extremely rare cases, developed de novo at
the embryo level. The genetic defect results mainly in a loss of cell growth control in target
endocrine cells, leading to tumor development.
Inherited endocrine tumors can be non-syndromic (the affected patient develops
only a single endocrine tumor during his/her lifetime) or syndromic (the patient devel-
ops multiple endocrine and non-endocrine tumors in different organs during his/her
lifetime) [1].
In addition to their specific endocrine and non-endocrine tumors, patients affected by
some of these genetic diseases can manifest alterations of bone and mineral metabolism,
presenting both as pathognomonic skeletal clinical features and/or non-specific bone and
mineral metabolism alterations (Table 1), which can be either secondary complications of
endocrine functioning primary tumors and/or a direct consequence of the gene mutation.
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3. Genetic Determinants of Inherited Endocrine Tumors and Bone
Bone is a highly dynamic tissue, undergoing life-long remodeling, which is the result
of a finely regulated balance between osteoclast bone resorption and osteoblast bone
formation [11] and which grants adaptation to external forces, the completion of bone
correct functions and the maintenance of skeletal and mineral metabolism health, as well
as self-repair after fractures.
In some patients affected by inherited endocrine tumors, the endocrine tumor-derived
hormone excess is responsible for the disturbance of the normal osteoclast–osteoblast bal-
ance and/or the alteration of correct skeletal modeling and bone and mineral metabolism
homeostasis, resulting in the secondary development of skeletal alterations, premature
bone mass loss, early onset osteoporosis and an increased risk of fragility fractures.
In some inherited endocrine tumors, a direct involvement of the inherited mutated
gene in alterations of bone and mineral metabolism, at cellular and molecular levels, is
strongly suspected, being primarily responsible for the development of specific pathog-
nomonic primary skeletal abnormalities.
In this section, we will discuss the ascertained molecular roles of the genes whose
germline mutations are responsible for inherited endocrine tumors in the regulation of skele-
tal modeling and remodeling, and/or in the control of mineral metabolism homeostasis.
3.1. CDC73 Gene
The CDC73 (Cell Division Cycle 73) gene encodes the parafibromin, a transcription
factor that is a core member of the Polymerase-Associated Factor 1 (PAF1) complex, which
regulates gene transcription and histone modifications.
Droscha et al. [12] investigated the role of parafibromin in osteoblast differentiation
and function by generating two murine models bearing a germinal conditional homozygote
deletion of the Cdc73 gene, one in Mesenchymal Stem Cell (MSC) progenitors and the
other in mature osteoblasts and osteocytes. Parafibromin was shown to be mandatory for
MSC differentiation and survival; the conditional complete loss of Cdc73 expression in
MSCs induced a high-rate apoptosis within the mesenchyme, blocking the correct organ
development at embryo day 11.5. Conversely, the mice completely missing Cdc73 in
osteoblasts and osteocytes were viable and lived well beyond one year. Surprisingly, they
manifested an overall significant increase in whole-body Bone Mineral Density (BMD).
Long bones appeared thicker and stronger. At the microarchitectural level, these bones
were characterized by large pores in the cortical bone area, undergoing an active bone
remodeling associated with a significantly increased mineral apposition rate. At the same
time, the osteocytes in the cortical bone had a high rate of apoptosis. The trabecular
bone presented a significant increase in both osteoblast number and osteoid bone volume,
coupled with a significantly decreased number of osteoclasts on the bone surface. At
transcriptional level, the knockout of the Cdc73 gene led to a decrease in the expression of
osteoblast-specific genes, mainly those encoding collagen and bone matrix proteins. Taken
together, these data suggest that parafibromin is necessary for MSC survival and, at the
same time, may act as a transcriptional repressor of activity of maturing osteoblasts, having
a possible direct role in the regulation of bone-forming cell differentiation and activity, and
bone homeostasis.
Ossifying fibromas are benign fibro-osseous neoplasms originating from pluripotent
MSC and are capable of forming mineralized bone tissue and cement. Although ossifying
fibromas are part of the Hyperparathyroidism-Jaw Tumors (HPT-JT) syndrome, a direct
role in the tumor development of either an haploinsufficiency or an aberrant intracellular
expression of parafibromin in bone-forming cells has not yet been clearly demonstrated.
Recently, Costa-Guda et al. [13] analyzed parafibromin expression and intracellular local-
ization in nine sporadic human non-syndromic ossifying fibromas. Four cases (44.4%)
showed a complete absence of nuclear parafibromin expression, one of them presenting
an aberrant cytoplasmatic expression of the protein. The full sequence of the CDC73 gene
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was available only for three cases, revealing the presence of one homozygote and one
heterozygote somatic inactivating mutation of the gene, both cases showing a complete
absence of nuclear parafibromin expression. Genomic DNA was not available for the
performance of germline mutation screening.
The data from the above-described studies provided, both in an animal model and
in humans, concordant evidence that the loss of the nuclear expression of parafibromin
in bone-forming cells may have an important, direct, role in the pathogenesis of ossifying
fibromas, confirming these skeletal neoplasms as a primary clinical manifestation and
direct consequence of the genetic defect in the CDC73 gene.
3.2. GCM2 Gene
The GCM2 (Glial Cells Missing Transcription Factor 2) gene encodes the Glial Cells
Missing Homolog 2 (GCM2) protein, a zinc finger-type transcription factor, which is essential
for the correct embryonic development of parathyroid glands. Recently, Yamada et al. [14]
showed that the reduction in GCM2 expression is responsible for a reduction in parathyroid
cell proliferation, an increase in parathyroid cell apoptosis and an attenuation of parathy-
roid function, demonstrating a key role of this protein in the maintenance, proliferation
and activity of adult parathyroids. Parathyroid glands are the principal actors of calcium
homeostasis, and subsequently, of bone mineralization. Thus, mutations of the GCM2 gene,
which alter the normal development, maintenance and function of these glands, have a
repercussion on the mineralization of the extracellular matrix of bone tissue. In particular,
gain-of-function mutations are responsible for parathyroid hyperplasia/adenoma with a
constant over-secretion of Parathyroid Hormone (PTH) and hypercalcemia, resulting in
increased osteoclast activity, a continuous release of calcium ion from bone tissue and a
subsequent reduction in mineralized bone mass, leading to early onset osteopenia and
osteoporosis with an enhanced praecox risk of fragility fractures.
3.3. APC Gene
The APC (Adenomatous Polyposis Coli) gene encodes the homonymous tumor sup-
pressor protein, which acts as a strong negative regulator of the Wnt signaling pathway by
directly binding the key transducer of this pathway, the β-catenin, and promoting its rapid
degradation. In the absence of a Wnt signal, cytosolic β-catenin is degraded by the ubiq-
uitination/proteasome system upon its binding and phosphorylation to a multi-protein
destruction complex that comprises APC. The binding of Wnt to LRP5 or LRP6 results
in the inactivation of the destruction complex and the subsequent accumulation of the
cytosolic β-catenin, favoring its nuclear translocation and the transcriptional activation
of Wnt target genes that leads to increased cell growth and reduced apoptosis. Mutated
APC proteins mimic the Wnt signal, leading to an increase in the cytosolic β-catenin and to
the consequent β-catenin-dependent induction of the expression of Wnt target genes. The
efficiency of β-catenin downregulation by the destruction complex is compromised in the
presence of a mutated APC protein, based on the site of the mutation [15]. The important
role of the Wnt cascade in the regulation of osteogenesis and in the pathophysiology of
a number of skeletal diseases is now well-established [16,17]. Indeed, increased levels
of the canonical Wnt/β-catenin signaling inhibit the expression and activity of SRY-Box
Transcription Factor 9 (SOX9) and stimulate the expression of Runt-related Transcription
Factor 2 (RUNX2), two commitment factors of chondrocyte and osteoblast differentiation,
respectively, decreasing chondrogenesis and promoting osteogenesis [18,19].
Miclea et al. [20] created a conditional knockout mouse model for the Apc gene in
Col2aI-expressing cells to investigate whether this gene was involved in the lineage commit-
ment of skeletal precursor cells. The homozygote Apc-knocked out animals died perinatally
due to severely impaired skeletogenesis, affecting both the axial and appendicular bone
segments. Analyses on homozygote embryos showed, in the Apc-knocked out cells, that the
complete absence of the Apc protein resulted in an accumulation of cytoplasmic β-catenin,
which, subsequently, translocated into the nucleus; highly elevated levels of β-catenin were
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found at all the sites of endochondral ossification and within the chondrocyte nucleus.
The cells lacked expression of both chondrogenic (i.e., Sox9) and osteogenic markers (i.e.,
Col2aI), demonstrating that the conditional loss of functional Apc in skeletal precursors
inhibited mesenchymal cell condensation and chondrogenic differentiation. Conversely,
the conditional heterozygous inactivation of Apc did not interfere with embryonic skeletal
development, postnatal growth or bone acquisition. Heterozygote Apc-knocked out em-
bryos, at various developmental stages, showed a normal spatio-temporal expression of
chondrogenic and osteogenic markers, and no detectable levels of β-catenin were found.
The micro-computed tomography of the distal femora performed in the heterozygote
Apc-knocked out mice, monitored for 12 weeks after birth, showed no significant differ-
ence compared to the wild type littermate mice in BMD, trabecular bone volume fraction,
trabecular number, trabecular thickness and trabecular separation. Microscopical analysis
of bones at 24 weeks after birth showed no important anomalies in the skull, ribs, vertebral
column and long bones. These data imply that the level of wild type Apc protein pro-
duced by a single functional Apc allele is sufficient to grant the Apc-mediated appropriate
β-catenin degradation and the correct Wnt-regulated skeletal modeling.
The importance of the APC protein for the correct skeletogenesis has also been shown
by Holmen et al. [21]. The mice with the conditional homozygote osteoblast-specific
deletion of the Apc gene manifested growth retardation and dramatic defects in bone
development, characterized by severe osteopetrosis associated with disturbances in bone
architecture and composition, leading to mortality within two weeks after birth. At bone
cell levels, the depletion of the Apc gene in osteoblasts, and the subsequent deregulation
of β-catenin signaling, caused a cell-autonomous osteoblast defect and, at the same time,
altered bone resorption, by dramatically reducing the number of osteoblasts, as a conse-
quence of the decreased expression of Receptor Activator of Nuclear Factor-κ B Ligand
(RANKL) and the increased expression of Osteoprotegerin (OPG).
Although variations in bone mass are not a clinical hallmark of Familial Adenomatous
Polyposis (FAP), two studies have shown a direct association between the presence of
an APC mutation and BMD values in humans [22,23]. A cross-sectional study on 30 FAP
patients bearing a germinal heterozygote mutation of the APC gene showed a significantly
higher mean BMD at the lumbar spine, total hip, femoral neck and trochanter in FAP
patients, with respect to age- and gender-matched healthy controls, in the presence of a
balanced bone remodeling, as displayed by the mean concentrations of procollagen type I
N-terminal propeptide and β-crosslaps being within the normal ranges [22].
Chew et al. [23] showed that individuals bearing a heterozygote deletion encompass-
ing part of the APC gene had a higher BMD at the forearm, spine and total hip compared
to subjects with two wild type copies of the gene.
Primary osteomas develop as disease-specific clinical manifestations in a percentage
of patients with FAP. These benign bone tumors affect bone segments characterized by
intramembranous ossification, an ossification process in which mesenchymal cells dif-
ferentiate directly into osteoblasts and deposit mineralized bone. APC mutations, that
are responsible for β-catenin accumulation and mimes the Wnt signaling, may suppress
the chondrogenic potential of the mesenchymal osteochondral progenitor cells, favoring
osteoblast differentiation and intramembranous ossification, and being, thus, directly
responsible for the development of osteomas.
3.4. MEN1 Gene
The MEN1 (Multiple Endocrine Neoplasia type 1) gene encodes a nuclear scaffold
protein named menin, which controls gene expression, cell signaling, cell growth, DNA
repair and histone modifications. A direct involvement of menin in the regulation of
osteogenesis has been widely demonstrated by in vitro and in vivo studies.
Wild type menin is required for the commitment, in vitro, of the pluripotential MSCs
to the osteoblast lineage. The specific menin inactivation by antisense oligonucleotides, in
MSC progenitors, inhibits osteoblastogenesis by blocking the Bone Morphogenetic Protein
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2 (BMP2) transcriptional activity of Smad1/5 and, thus, antagonizing Alkaline Phosphatase
(ALP) activity and the expression of the key osteoblast transcription factor RUNX2, and of
the protein of the bone extracellular matrix-like type I collagen and Osteocalcin (OCN) [24].
The inactivation of menin has no effect on the expression of adipogenic and chondrogenic
markers in MSCs induced to differentiate into the adipocyte or the chondrocyte lineage,
respectively. Conversely, menin inactivation in the murine osteoblastic cell line MC3T3-
E1 has been shown to not affect BMP2-stimulated ALP activity nor the expression of
RUNX2 and OCN, confirming the inductive role of menin in the commitment of osteoblast
precursors, but not on mature osteoblasts. In addition, the fact that the stable inactivation
of menin in MC3T3-E1 cells increased ALP activity, mineralization and the expression
of type I collagen and OCN indicates that menin exerts an inhibitory role in osteoblast
later differentiation [24]. In normal conditions, menin interacts physically and functionally
with BMP2, and with the BMP2 signaling molecules Smads 1/5, in still uncommitted
MSCs, inducing their osteoblast differentiation [25]. After the osteogenic commitment, the
interaction of menin with BMP2 and Smads 1/5 is lost, in the differentiated osteoblasts,
in which menin physically interacts with Smad3, positively regulating the Transforming
Growth Factor-β (TGFβ)/Smad3 pathway and negatively regulating the BMP2/Smad1/5-
and the RUNX2-induced transcriptional activities and, thus, leading to the inhibition of
osteoblast late-stage differentiation [26].
The conditional homozygote knockout mice for the Men1 gene in mature osteoblasts
showed significantly reduced BMD compared to the wild type animals [27]. Bone mass
reduction affected both trabecular and cortical bone, with significantly reduced trabecu-
lar bone volume and number, associated with an abnormal structure of trabeculae, and
significantly reduced cortical bone volume, surface and thickness. At the cellular levels,
the mutated mice had significantly reduced osteoblast and osteoclast numbers and in-
creased osteocyte numbers, coupled with a reduced mineral apposition rate. The isolated
osteoblasts from the knockout mice showed a reduced expression of osteoblast markers,
together with an increased expression of both osteocyte markers and pro-apoptotic genes.
Conversely, a transgenic mouse model overexpressing menin in osteoblasts manifested a
gain of bone mass, increased bone volume and trabecular numbers, increased numbers of
mature and active osteoblasts, increased osteoblast differentiation markers (Runx2, OCN
and type I collagen) and an enhanced ALP activity and mineral apposition rate.
Liu et al. [28] confirmed that the conditional homozygote depletion of Men1 in the
osteoblast lineage of mice caused osteoporosis. The Men1 deficiency specifically induced
in osteocytes, but not in early differentiated osteoblasts, enhanced osteoclastogenesis
(increased osteoclast numbers and surface) and bone porosity (reduction in the number of
trabeculae and increased trabecular separation) in vitro and in vivo. Osteocytes lacking
Men1 showed an enhanced secretion of C-X-C Motif Chemokine 10 (CXCL10), a known
osteoclastogenesis-inducing factor.
Luzi et al. [29] showed that menin induces, in human MSCs induced in vitro to
differentiated into osteoblast lineage, the expression of the miR-26a, an osteogenesis-
inhibitor microRNA that negatively regulates the expression of SMAD1 during osteoblast
differentiation of the MSCs [30], acting as a transcription factor and directly occupying
the miR-26a gene promoter. These data indicate the miR-26a-SMAD1 as an additional
regulative pathway by which menin inhibits the osteoblast late-stage differentiation of
committed precursors.
Patients affected by MEN1 syndrome do not develop any primary bone affections,
directly associated and derived by MEN1 mutations. MEN1 patients have a higher risk
of early onset osteoporosis, with respect to the general population of the same age [5],
attributed to primary hyperparathyroidism (PHPT) and other endocrine dysfunctions
typical of the syndrome. A direct role of MEN1 gene mutations in the premature bone
mass loss has not been demonstrated; however, given the fact that menin protein has
been shown to be directly involved in the regulation of osteoblastogenesis, a synergical
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pro-osteoporotic effect of menin haploinsufficiency in mesenchymal stem cells and bone
forming cells cannot be excluded.
3.5. RET Gene
The RET (REarranged during Transfection) gene encodes the homonym tyrosine
kinase transmembrane receptor, RET. Binding of the ligands stimulates RET receptor
dimerization and the activation of downstream signaling pathways, which play a role in
cell survival, proliferation, differentiation and migration.
Patients affected by Multiple Endocrine Neoplasia type 2B (MEN2B) develop typical
skeletal abnormalities, not manifesting in the Multiple Endocrine Neoplasia type 2A
(MEN2A) form.
The murine embryonal fibroblast NIH 3T3 cell line expressing RET-MEN2B mutants
or stimulated with the Glial Cell Line-Derived Neurotrophic Factor (GDNF), a biologi-
cal ligand of the RET receptor, showed a highly induced expression of Stanniocalcin 1
(STC1) [31], a protein involved in early skeletal development and joint formation [32].
Conversely, the NIH 3T3 expressing RET-MEN2A mutants had no effect on the expression
of STC1, suggesting that the STC1 gene expression may have a role in the development of
MEN2B-specific bone phenotype.
A comparison of the gene expression profile between the specimens of Medullary
Thyroid Carcinoma (MTC) from MEN2A and MEN2B patients showed that the malignant
C cells of MEN2B MTCs expressed high levels of Chondromodulin 1 (CHM1) [33], a
secreted glycoprotein known to be a regulator of cartilage and bone growth that is normally
expressed in proliferating chondrocytes of the growth plates. Interestingly, all the MEN2B
MTC patients with skeletal abnormalities had high CHM1 expression, suggesting that the
CHM1 aberrant expression in the MEN2B MTC, in early infancy and childhood, could be
responsible for alterations at the growth plates of developing bones, leading to the skeletal
abnormalities that characterize the MEN2B form of the syndrome.
In addition, GDNF, one of the major ligands of the RET receptor, has been shown
in vitro to induce the migration of Bone Marrow MSCs (BMMSCs) and stimulate osteoge-
nesis [34]. The pre-osteoclast conditioned medium was demonstrated to contain GDNF
that bound GFRα1 and recruited the co-receptor RET, inducing RET phosphorylation in
BMMSCs, resulting in cell migration and differentiation toward the osteoblast lineage.
Inhibition of the GDNF/GFRα1/RET signaling pathway blocked both BMMMSC migra-
tion and osteogenic differentiation. These data indicate the existence of GDNF-mediated
osteoclast-osteoblast crosstalk, which leads to BMMSC migration and osteogenic differenti-
ation via the activation of RET tyrosine kinase activity. Mutant RET receptors, constitutively
activated for their tyrosine kinase activity, could mimic this GDNF/GFRα1/RET signaling,
being responsible for the development of bone manifestations in MEN2B.
Multiple Endocrine Neoplasia type 2 (MEN2) is characterized by a strict genotype-
phenotype correlation, not only limited to endocrine tumor development but also to the
displaying of pathognomonic skeletal abnormalities that manifest only in patients with the
MEN2B form. The RET mutations causing MEN2A affect the extracellular domain of the re-
ceptor miming a constitutive binding with the ligand, while the mutations causing MEN2B
are located in the two intracellular tyrosine kinase domains of the receptor, resulting in a
constitutively activated tyrosine kinase activity; only the latter mutations are responsible
for the development of typical skeletal features, presumably via the specific induction of the
overexpression of STC1 and CHM1 proteins. Conversely to all the other causative genes of
hereditary endocrine tumors, which are tumor suppressor genes, RET is a proto-oncogene,
and a monoallelic activating mutation is sufficient to alter the function of the receptor and
lead to the development of the clinical phenotype, including skeletal abnormalities.
3.6. CDKN1B Gene
The CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) gene encodes the p27kip1 cyclin-
dependent kinase inhibitor that binds to and prevents the activation of cyclin E-CDK2
Genes 2021, 12, 1286 12 of 20
and cyclin D-CDK4 complexes, negatively regulating the cell cycle progression at G1.
Some in vitro and in vivo studies have indicated a possible involvement of p27kip1 in the
regulation of osteoblast differentiation from mesenchymal precursors.
The in vitro culture of bone marrow-derived progenitors, established from mice with
the homozygote deletion of the Cdkn1b gene, showed that the complete ablation of p27kip
resulted in a precocious proliferation of these cells and in an acceleration of their osteoblast
differentiation, with respect to those of wild type littermate animals [35]. In fact, when the
p27 kip-lacking bone progenitor cells were induced to differentiate into osteoblasts, they
showed a higher ALP positive staining, an increased number and size of the osteogenic
colonies, and an earlier mineralization of the extracellular matrix, compared with cultures
from the wild type mice. In the proliferating osteoblast precursors from the wild type
mice, the levels of p27kip1 were low, and they substantially increased during osteogenic
differentiation. The p27 kip1 null mice showed an increased size of long bone and an
increased width of diaphyseal cortical bone shafts compared to wild type littermates, with
both the osteoblasts and osteoclasts on trabecular bone surfaces of a normal appearance
and a greater cellular density within the bone marrow.
Zhu et al. [36] showed that the homozygote p27kip-null mice (p27−/− mice) presented
an increased length of long bones, size of epiphyses, BMD, trabecular bone volume, number
of mature osteoblasts and of chondrocytes positive for the proliferating cell nuclear antigen
staining, as well as ALP-, type I collagen- and OCN-positive bone areas. When a compound
null mouse model bearing both the biallelic deletion of the Cdkn1b gene and the homozygote
mutation of the parathyroid hormone-related peptide (Pthrp) KI (p27−/−Pthrp KI mice)
was analyzed, it showed all the above listed bone and cartilage paraments being reduced
with respect to the wild type mice but increased with respect to the Pthrp KI mice. These
data suggest that the complete depletion of p27kip in the homozygote Pthrp KI mice can
partially rescue defects in skeletal growth and osteoblastic bone formation by enhancing
endochondral bone formation and osteogenesis. Given the fact that p27kip directly interacts
with the C-terminal region of PTHrP, it is conceivable that the p27kip pathway may act
downstream to PTHrP in the regulation of skeletal growth and development.
To date, very few clinical cases of Multiple Endocrine Neoplasia type 4 (MEN4) have
been reported worldwide, and targeted studies on bone complications in this syndrome
are totally missing. As for MEN1, of which MEN4 is a clinical phenocopy, the prema-
turely manifesting reduced bone mass is mainly attributed to PHPT, and it is thought
to manifest later in life and in a less severe degree, with respect to MEN1 patients, ac-
cordingly to a later onset and milder PHPT that characterizes MEN4. A direct role of
the p27 kip1 haploinsufficiency in altering bone metabolism in MEN4 patients remains to
be demonstrated.
3.7. PRKAR1A Gene
The PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit α) gene
encodes the type 1A regulatory subunit of the tetrameric cAMP-dependent Protein Kinase
A (PKA). While the inactivating mutations in the PRKAR1A gene are responsible for Carney
Complex (CNC), the gain-of-function mutations of this gene have been identified in patients
with acrodysostosis, a heterogeneous group of rare skeletal dysplasia [37,38], suggesting
the possibility of a direct involvement of the PKA-regulated pathway in regulating bone
modeling and/or remodeling, and presumably being responsible for the development of
both chondrodysplasia and osteochondromyxomas when deregulated.
The heterozygote Prkar1a activating point mutation R368X knock-in mice (Prkar1a [R368X]/[+]
mice) had chondrodysplasia and peripheral acrodysostosis affecting the endochondral
skeleton, which resulted in shorter tails, shorter length and shorter forelimbs and hindlimbs,
compared to their wild type littermates. Brachydactyly and snout dysostosis were also
present, and BMD and bone surface were both significantly reduced [38]. The mutant
mice presented a striking delay in the mineralization of the cartilage and epiphyseal
secondary ossification centers of forelimb and hindlimb bones, accompanied by modi-
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fications in the proliferative and hypertrophic chondrocyte layers. The data from this
study showed the importance of the Prkar1a subunit of PKA in the correct regulation of
endochondral ossification; however, no defect in the endochondral bone development (i.e.,
no increased proliferation or decreased chondrocyte differentiation) has been described in
human CNC patients.
Conversely, the heterozygote knockout mice for the Prkar1a gene (Prkar1a+/− mice),
which mimic the Prkar1a subunit haploinsufficiency of the CNC, developed, in about 80%
of cases, tumoral lesions on the tail vertebrae and the sacroiliac region, which arise from
cells of the osteoblast lineages [39] and present a histological and cytological similarity to
the osteochondromyxomas that develop in human CNC patients. As previously demon-
strated in bone tumors arising in human patients with a PRKAR1A mutation [40], tumoral
osteoblasts from the Prkar1a+/− mice showed a significantly elevated level of both a total
and a free PKA enzyme.
Osteochondromyxomas are primary, extremely rare, benign bone tumors, manifesting
prevalently within the CNC syndrome, composed by a mix of chondroid and osteoid
matrix. Data from the study of Pavel et al. [39] indicated that this bone tumorigenesis is
predominantly driven by an excessive activation of PKA signaling, as a direct consequence
to a PRKAR1A inactivating mutation.
3.8. PTEN Gene
The PTEN (Phosphatase and TENsin Homolog) gene encodes a phosphatidylinositol-
3,4,5-trisphosphate 3-phosphatase that negatively regulates the PI3K/AKT/mTOR signal-
ing pathway and cell survival, proliferation and migration. The PTEN/PI3K/AKT axis has
been involved in embryonic bone development and fracture healing.
The conditional knockout of the Pten gene in osteoblasts of a mouse model resulted in
an increased fracture healing, with a larger and more ossified callus and an improvement of
both the early intramembranous bone formation and the later endochondral bone formation
during the healing process [41], indicating that the inhibition of PTEN may have a clinical
application for enhancing fracture healing in cases of bone non-unions.
The mice with the homozygote conditional deletion of the Pten gene in osteoblasts
showed a significantly increased whole-body BMD, compared to wild type littermates,
that progressively increased throughout life [42]. The mutant mice had a pronounced
higher bone volume, both at the cortical and trabecular bone, with an increased cortical
thickness in the femur and with the trabeculae being thicker and less separated, than those
of the controls. These data suggest that the loss of Pten could influence bone formation
via intramembranous ossification. At bone cell levels, in vitro cultures of Pten-deficient
osteoblasts showed a constitutive activation of Akt signaling and target genes and a
reduction in the apoptosis rate, with respect to wild type control osteoblasts.
The mice with the conditional homozygote deletion of the Pten gene in osteo-chondroprogenitor
cells showed, as did mouse mutants on the osteoblasts, a bone overgrowth, and confirmed
the development of an increased skeletal diameter, increased cortical thickness and en-
hanced number of trabeculae [43]. The chondrocytes, within bone growth plates, appeared
disorganized, showing, compared to the control mice, a less well-defined demarcation
between the proliferative zone and the beginning of the prehypertrophic region. The
primary spongiosa exhibited increased numbers and sizes of disorganized trabeculae,
and the nascent perichondrial bone collar showed an accelerated hypertrophic osteoblast
differentiation and an enhanced apposition of matrix proteins.
Taken together, these two studies show that PTEN is an important modulator in
determining the extent of normal cartilage and bone development and, thus, skeletal size.
The PTEN function in chondrocytes is essential for inhibiting dyschondroplasia. As a
consequence, the loss of PTEN protein may have a direct pathogenic role in the skeletal
manifestations observed in patients with the Cowden/PTEN hamartoma tumor syndrome.
Bone morphogenetic protein 9 (BMP9) is one of the most efficacious osteogenic cy-
tokines. PTEN has been demonstrated, in vitro, to be downregulated by BMP9 during the
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osteoblast differentiation of mouse embryonic fibroblasts [44]. Some years later, Li et al. [45]
demonstrated the existence of a reciprocal feedback between PTEN and BMP9, showing
a direct inhibitory action of PTEN on the osteogenic potential of BMP9, which resulted
in the inhibition of PI3K/AKT signaling. In vitro analyses showed that PTEN reduced
the BMP9-induced osteogenic differentiation of murine C3H10T1/2 MSCs by inhibiting
both the mRNA and protein levels of Runx2 and OCN, and by inhibiting ALP activity and
mineralization. During osteoblastogenesis, the Wnt10b, a secreted protein member of the
canonical Wnt signaling, is upregulated by BMP9, acting as a bone formation promoter and
a mediator of the osteogenic potential of BMP9, and favoring the differentiation toward the
osteogenic lineage at the expense of adipogenesis. In the C3H10T1/2 cell line, Wnt10b was
demonstrated to be able to partially reverse the inhibitory effect of PTEN on BMP9-driven
osteogenesis, suggesting that PTEN may inhibit the osteogenic potential of BMP9 by
negatively regulating Wnt10b expression, with a mechanism that is still unclear [45].
A similar inverse association was also demonstrated between PTEN and BMP2 [46]
in the C3H10T1/2 cell line. PTEN inhibited the BMP2-induced osteoblast differentiation
of MSCs at the osteoblast lineage commitment level and at the early and late stages
of osteogenic differentiation, while BMP2 repressed PTEN expression, leading to the
activation of PI3K/AKT and to osteogenesis. PTEN was shown to inhibit the proliferation,
but promote apoptosis, of the C3H10T1/2 MSCs. The authors studied the role of the
PTEN/PI3K/AKT signaling pathway in ectopic calcification by establishing a specific
animal model via the implantation of human recombinant BMP2 into the muscle tissue of
mice to induce soft tissue ossification. The inactivation of the PI3/AKT signaling, by PTEN,
markedly suppressed the BMP2-induced ectopic endochondral calcification of muscles [46].
Both these studies supported the notion that the activation of the PI3K/AKT signal-
ing pathway is a key step for both BMP2- and BMP9-induced osteoblastogenesis, bone
formation and endochondral ossification. Therefore, the PTEN/PI3K/AKT axis represents
a potential target for either favoring endochondral fracture repair or for the molecular
prevention/therapy of the heterotopic ossification of soft tissues.
3.9. NF1 Gene
The NF1 (Neurofibromin 1) gene encodes neurofibromin 1, a negative regulator of the
Ras signal transduction pathway.
Several studies have documented a decreased BMD in individuals with neurofibro-
matosis type 1 (NF1) [47–52], suggesting that the NF1 haploinsufficiency may contribute
to abnormal bone remodeling, either directly or indirectly by aberrant Ras signaling,
potentially predisposing NF1-affected individuals to skeletal abnormalities and osteoporo-
sis. Pathognomonic bone manifestations in NF1 syndrome are congenital and primary
dysplasias, implying a direct role of an NF1 defect in the alterations of both skeletal devel-
opment and bone homeostasis. The MSCs derived from Nf1+/− mice showed an impaired
osteoblast differentiation, presumably as a direct consequence of Nf1 protein haploinsuffi-
ciency [53]. However, the somatic loss of heterozygosity at the NF1 locus, found in bone
cells from dysplasia and pseudoarthrosis of the tibia in NF1 patients, suggests that the
biallelic loss of NF1 function is likely to be required to cause the bone phenotype in human
NF1 syndrome, and confirms that the neurofibromin-Ras signal transduction pathway is
directly involved in tibial bone dysplasia [54].
A transcriptome profiling of bone cells, derived from a tibial pseudoarthrosis of a NF1
patient, showed that EREG and EGFR1 genes, encoding, respectively, epiregulin and its
receptor Epidermal Growth Factor Receptor 1, were among the NF1-deficiency-associated
top up-regulated genes [55]. An over-expression of the epiregulin gene and protein was
shown in human bone cells bearing NF1 double hit mutations [56]. A three-time over-
expression of epiregulin was also confirmed in Nf1-deficient mouse bone marrow stromal
cells, with respect to wild type controls, both at the mRNA and protein levels, showing
that this molecular signature is conserved among mice and humans, and it may have a
direct role in the bone abnormalities of the NF1 syndrome.
Genes 2021, 12, 1286 15 of 20
The study of the role of NF1 inactivating mutations in bone modeling and remodeling
in vivo is difficult since the homozygote Nf1−/− mice die in utero before bone formation
can be studied, and heterozygote Nf1+/− mice have been shown to not manifest any
bone phenotypes.
Kuorilehto et al. [57] studied Nf1 gene and protein expression profiles in bone tissues
from Nf1+/− and wild type mice at 12.5–15.5 embryonic days and in adulthood. Nf1
mRNA and protein were both high expressed in resting, maturation and hypertrophic
chondrocytes at the growth plates. The expression patterns of Nf1 mRNA and protein
in the growth plate cartilages of femora and tibias of adult mice were similar to those
observed in the embryonic counterparts. The synovial cartilage also resulted as positive
for Nf1 mRNA and protein expression. The osteoclasts, osteoblasts and osteocytes in the
periosteum of the adult animals all appeared strongly positive for neurofibromin protein
expression. No differences were found for neurofibromin expression between the mutant
and wild type animals, both at embryo levels and adulthood, being consistent with the
absence of skeletal abnormalities in the heterozygote Nf1 mutant mice. A neurofibromin-
mirroring negative labeling for the phosphorylated p44/42 MAPK complex, as the result of
the Ras pathway activation and the consequent p42 and p44 MAPK phosphorylation, was
found in proliferative, maturing and synovial cartilages of both the Nf1-deficient and wild
type skeletal tissues from the embryonic and adult mice. The hyperthropic chondrocytes
of the Nf1+/− embryos presented a high expression of phosphorylated p44/42 MAPK,
suggesting that the activation of the Ras-MAPK pathway, resulting from NF1 protein
haploinsufficiency, may be involved in the development of congenital skeletal dysplasias
in NF1 patients.
Kolanczyk et al. [58] generated a mouse model bearing the heterozygote conditional
inactivation of the Nf1 gene in undifferentiated MSCs of the developing limb skeleton
(Nf1Prx1 mice). Similar to NF1-affected patients, the Nf1Prx1 mice showed retarded and
reduced bone growth and abnormal growth plates and manifested the anterolateral bowing
of the tibia that started in the uterus, was already present at birth, and progressively
worsened after two weeks of age. The affected bones were characterized by a decreased
calcium content and the increased porosity of the cortical areas. The in vitro analysis
of osteoblast precursors extracted from Nf1Prx1 mice, and induced to differentiate into
osteoblasts, showed a significant reduction in both ALP activity and extracellular matrix
mineralization, with respect to those from wild type littermates. Mutant osteoblasts showed
a strong induction of osteopontin, a marker of the early differentiation stage and a known
inhibitor of calcification, and a reduction in the expression of integrin-binding sialoprotein
and OCN, two markers of the terminally differentiated mature osteoblasts. Therefore, the
loss of Nf1 function in osteoblast precursors resulted in an accumulation of incompletely
differentiated osteoblasts and, ultimately, in abnormal bone formation. In addition, the
Nf1Prx1 mice manifested cartilaginous fusions of the hip joints in all the mutated animals,
varying from partial to complete fusions, a phenotype that is not observed in NF1 syndrome.
The joints from the wild type animals showed a normal nuclear distribution of Sox9, an
essential regulator of chondrocyte differentiation from precursors, at embryonic day 13.5,
with a shift of Sox9 localization to the cytoplasm at 14.5 embryonic days, which reduced
chondrocyte activity and favored correct bone growth. Conversely, the Sox9 nuclear
localization persisted in the cartilage joint cells from the Nf1Prx1 mice, leading them to
remain active chondrocytes, concurring with the joint fusion [58].
The data from the studies described above confirmed NF1 as an important modulator
of skeletal development and growth; somatic loss of the wild type protein in osteoprogeni-
tor cells is presumably a key step in the development of NF1-associated bone phenotypes.
3.10. TSC1 and TSC2 Genes
The TSC1 (Tuberous Sclerosis 1) gene encodes for hamartin, a protein that plays a key
role in the regulation of cell adhesion, while the TSC2 (Tuberous Sclerosis 2) gene encodes
for tuberin, a GTPase-activating protein that regulates the GTP binding and hydrolyzing
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activity of the Ras protein superfamily, helping to regulate cell growth, proliferation and
differentiation. These two proteins bind to each other, via their respective coiled-coil
domains, to form an intracellular hamartin-tuberin complex that negatively regulates
the Mammalian Target of Rapamycin Complex 1 (mTORC1) signaling, which is a major
regulator of anabolic cell growth. Disruption of the hamartin-tuberin complex, through
the loss (inactivating mutations) of either the TSC1 or TSC2 gene, results in a constitutive
activation of mTORC1.
In recent decades, few studies have investigated the role of mTORC1 signaling in bone
cells. Unfortunately, homozygote knockout mice, either for Tsc1 or Tsc2 genes, present an
early embryonic lethality that prevents the possibility to study the molecular mechanisms
by which the dysregulated mTORC1 signaling affects postnatal skeletal development and
bone metabolism.
Fang et al. [59] generated a conditional knockout mouse model selectively lacking both
copies of the Tsc1 gene in Neural Crest-Derived Cells (NCDCs), which normally contribute
to the formation of a majority of craniofacial bones. The mutated animals manifested a
spectrum of sclerotic craniofacial bone lesions (thickened frontal calvaria, zygomatic bones
and nasal bones), comparable to the patients affected by Tuberous Sclerosis Complex (TSC);
no increase in the parietal bones of mesodermic origin was found. The Tsc1 deletion-caused
mTORC1 hyperactivation in NCDCs led to an enhanced proliferation of the osteoprogenitor
pool at an early postnatal stage, associated with an increased bone formation rate and
elevated mineral apposition rate. No effect of mTORC1 signaling was exerted on the
number and activity of osteoclasts. The mouse heterozygote for the conditional Tsc1
deletion had a similar bone thickness to the wild type littermates, indicating that the Tsc1
haploinsufficiency alone does not affect the osteogenic differentiation of NCDCs.
When the conditional homozygote deletion of the Tsc1 gene is induced in Osterix-
positive cells, mutant mice show a significantly decreased trabecular bone mass, associated
with contemporary reduced osteoblastogenesis and enhanced osteoclastogenesis, and with
increased adiposity of the bone marrow [60]. At the bone cell level, hamartin-deficient
murine bone marrow stromal cells showed decreased proliferation, reduced early and
terminal osteoblast differentiation and increased adipogenic differentiation. Main mas-
ter osteoblastic transcription factors (Runx2 and Osterix) and osteoblast differentiation
markers (ALP, Col1a1 and bone sialoprotein) all showed a decreased mRNA expression,
while the expression of master adipogenic transcription factors resulted increased (i.e.,
peroxisome proliferator-activated receptor γ, fatty acid binding protein 4, adiponectin,
enhancer-binding protein α and zinc finger protein 423) [60]. Tsc1 deletion in Osterix-
positive cells led to an mTORC1-dependent downregulation of the Wnt/β-catenin sig-
naling by decreasing the total and active β-catenin protein levels via the non-canonical
Notch1-mediated GSK3-independent active β-catenin degradation, which resulted in a
decreased mRNA expression of the Wnt/β-catenin target genes.
A further piece in the understanding of the role of the TSC1 gene in bone metabolism
was recently shown by Liu et al. [61]. By using a mouse model with the conditional ho-
mozygote deletion of the Tsc1 gene in osteocytes, the authors showed that the constitutive
activation of the mTORC1 signaling in osteocytes enhanced RANKL expression, leading to
osteoclast formation, and, at the same time, markedly reduced the expression of sclerostin,
a secreted glycoprotein that strongly inhibits osteoblast differentiation and bone formation,
via the upregulation of Sirt1, a histone deacetylase repressor of the sclerostin gene expres-
sion. As a consequence, the mutated mice manifested osteosclerosis with enhanced bone
formation and increased BMD.
One study investigated, in vivo and in vitro, the effect of the biallelic Tsc2 deple-
tion in murine osteoblasts, showing that the Tsc2 deficiency-induced mTORC1 activation
caused the accumulation of disorganized bone tissue as a consequence of an excessive
number of active osteoblasts, indicating that tuberin is required for normal osteoblast
differentiation [62].
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Sclerotic bone lesions (SBLs), presumably originating from cells of the neural crest,
are a common skeletal manifestation in patients affected by Tuberous Sclerosis (TSC)
syndromes. They manifest in about 84% of mutated patients (47.2% with mutated TSC1
gene and 52.8% with mutated TSC2 gene), but only in 14% of patients without TSC1 or
TSC2 mutations [63], suggesting that the inactivation of the hamartin-tuberin complex,
and the subsequent hyper-activation of mTOR signaling, may have a direct role in the
development of SBLs, as the studies described above also appear to confirm.
4. Conclusions
Except for pathognomonic skeletal abnormalities related to some of the syndromic
inherited endocrine tumors that are commonly included in the diagnosis of the disease and
that are normally described and discussed in the clinical cases, the majority of bone and
mineral metabolism affections in these congenital disorders have long remained poorly
investigated in the clinical practice, and are still largely missing in the medical literature,
guidelines and patients’ medical records.
However, despite the fact that these clinical manifestations are less severe than the
associated endocrine tumors, they are a cause of morbidity and disability and contribute to
reduce the quality of life of affected patients.
• Medical interventions aimed to prevent the development of some of these bone
affections, such as osteopenia and osteoporosis, or to early diagnose, control and treat
those that cannot be prevented, should become part of the clinical and therapeutic
management of hereditary endocrine tumors.
• A more and more detailed knowledge of these bone manifestations, deriving from the
routine description of their clinical aspects and biological features by clinicians and
from their inclusion in the clinical guidelines of inherited endocrine tumors, as well as
from basic research and clinical studies investigating the molecular roles of “cancer
genes” in the regulation of bone development and metabolism in physiological and
pathological conditions, is a key point for designing better clinical managements of
these skeletal affections, and for possible future targeted therapies.
• Since some of the mutated genes responsible for the inherited endocrine tumor phe-
notypes and the subsequent haploinsufficiency of their encoded proteins, such as
parafibromin, APC, PRKAR1A, PTEN, NF1, tuberin and hamartin, were shown to be
directly involved in the development of the syndrome-specific skeletal abnormalities,
targeting their downstream dysregulated signaling pathways represent potential tar-
gets for treatments not only of the tumor manifestations but also of the bone affections.
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